JACKSONVILLE, Fla., June 24, 2008 (PRIME NEWSWIRE) -- BodyTel Scientific Inc. (OTCBB:BDYT), a developer of wireless telemedical devices, announces today that it has, through its wholly owned subsidiary BodyTel Europe GmbH, entered into an exclusive distribution agreement with Diabetes Supplies Ltd. (DSL), a well known distributor of medical supplies in New Zealand. Beginning in the third quarter of 2008, BodyTel's new partner, Diabetes Supplies, intends to begin offering BodyTel's blood glucose monitoring and diabetes management system, GlucoTel(tm), in New Zealand (the "Territory"). Pursuant to the terms of the distribution agreement, BodyTel granted DSL the right to exclusively market the GlucoTel in the Territory for a term of one year. Diabetes Supplies Ltd. is also responsible for all distribution, compliance and marketing costs relating to the sale of the products in the Territory.
Walter Stahl, CEO of Diabetes Supplies Ltd., stated, "DSL has a tremendous reach in the New Zealand diabetes community, extending to patients and caregivers. We are delighted and excited to begin distributing the GlucoTel system in New Zealand, which we believe represents the future of glucose testing globally. Comprehensive knowledge and complete access to disease related data and information are the keys to effective disease management. The BodyTel approach is a giant step forward in this regard."
Diabetes Supplies Ltd. is a specialist distributor in New Zealand (www.diabetessupplies.co.nz) focused entirely on diabetes related products. Through this focus, DSL strives to achieve maximum penetration in the market and to reach every person with diabetes directly, offering a comprehensive range of products and services, including dispensing of prescriptions of glucose test strips and meters.
"We continue to add high quality distributors, and Diabetes Supplies Ltd. is no exception," said Stefan Schraps, CEO of BodyTel. "We chose DSL due to their extensive knowledge of diabetes management. As we begin our sales and marketing efforts, it is especially important to have knowledgeable distributors with extensive territorial reach."
BodyTel's first market-ready product is the GlucoTel(tm) blood glucose meter. It is part of the GlucoTel(tm) system, a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and doctors in the treatment of diabetes and its corollary diseases. GlucoTel(tm) electronically measures the blood sugar level and then sends it via Bluetooth to the patient's cell phone. After that, the data is automatically transmitted to an online database via internet connection and stored on a long-term basis. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or caregivers, can access the data via internet at any time using a secure login.
About BodyTel
BodyTel is a German-American telehealth company that specializes in telemedical monitoring and management systems for chronic diseases. The company combines its know-how in telecommunications, internet and medical technology/diagnostics to create new products and services for the changing needs of global health. BodyTel products are designed not only to simplify home monitoring by patients, but also to ease the communication of 'measured body values' to healthcare professionals or other caregivers by bridging the gap between the patient and the caregivers instantaneously and in real-time. BodyTel's products -- GlucoTel, PressureTel and WeightTel -- are each at different stages of development and approval processes.
Further information can be found at www.bodytel.com.
Forward Looking Statements
Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur. Forward-looking statements in this news release include: that Beginning in the third quarter of 2008, BodyTel's new partner, Diabetes Supplies, intends to begin offering BodyTel's blood glucose monitoring and diabetes management system, GlucoTel(tm), in New Zealand, and that as we begin our sales and marketing efforts, it is especially important to have knowledgeable distributors with extensive territorial reach. It is important to note that the Company's actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company's Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company's periodic reports filed with the SEC. These reports are available on our investor relations website at www.bodytel.com and on the SEC's website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.